Cargando…

Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood following a Second Relapse

Although hematopoietic stem cell transplantation (HSCT) has been considered to be the only way for potential cure of relapsed acute myeloid leukemia (AML), there has been no report on a third HSCT in patients with multiple relapsed AML. Here, we report a case of 53-year-old female who received a suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Suk-young, Kurita, Naoki, Maie, Koichiro, Seki, Masanori, Yokoyama, Yasuhisa, Suzukawa, Kazumi, Hasegawa, Yuichi, Chiba, Shigeru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934324/ https://www.ncbi.nlm.nih.gov/pubmed/24660078 http://dx.doi.org/10.1155/2014/918708

Ejemplares similares

Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
por: Maie, Koichiro, et al.
Publicado: (2014)

Early Pathologic Findings of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation: A Proposal from a Case
por: Nakamoto-Matsubara, Rie, et al.
Publicado: (2012)

Relapse of Acute Myeloid Leukemia with t(16;21)(p11;q22) Mimicking Autoimmune Pancreatitis after Second Allogeneic Bone Marrow Transplantation
por: Kamada, Yuhei, et al.
Publicado: (2011)

Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
por: Nishikii, Hidekazu, et al.
Publicado: (2019)

The Road Map for Megakaryopoietic Lineage from Hematopoietic Stem/Progenitor Cells
por: Nishikii, Hidekazu, et al.
Publicado: (2017)

Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma
por: Hattori, Keiichiro, et al.
Publicado: (2018)

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature
por: Miki, Kosuke, et al.
Publicado: (2018)

Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Ninomiya, Haruhiko, et al.
Publicado: (2015)

Clinical significance of disease‐specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma
por: Hattori, Keiichiro, et al.
Publicado: (2017)

Role of Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
por: Carella, Angelo Michele
Publicado: (2012)

Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure
por: Suma, Sakurako, et al.
Publicado: (2021)

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events
por: Ishitsuka, Kantaro, et al.
Publicado: (2022)

Spontaneous reduction of an incarcerated gravid uterus in the third trimester
por: Takami, Mio, et al.
Publicado: (2016)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Disease-specific mutations in mature lymphoid neoplasms: Recent advances
por: Sakata-Yanagimoto, Mamiko, et al.
Publicado: (2014)

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
por: Prockop, Susan E., et al.
Publicado: (2023)

Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment
por: Rosamilio, R., et al.
Publicado: (2016)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
por: Hosono, Naoko, et al.
Publicado: (2021)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2015)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2017)

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma
por: Wilke, Christopher, et al.
Publicado: (2017)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
por: Al-Juhaishi, Taha, et al.
Publicado: (2022)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Second Hematopoietic Stem Cell Transplantation for Leukemia Relapsing after Myeloablative T Cell Depleted Transplants Does Not Prolong Survival
por: McIver, Zachariah A., et al.
Publicado: (2013)

Characteristics of hematopoietic stem cells of umbilical cord blood
por: Hordyjewska, Anna, et al.
Publicado: (2014)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?
por: Ramiz, Sarah, et al.
Publicado: (2023)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
por: Kaye, S. B., et al.
Publicado: (2011)

Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractory Cytomegalovirus Retinitis after Unrelated Umbilical Cord Blood Transplantation
por: Li, Na, et al.
Publicado: (2022)

P1397: THIRD-PARTY MULTIVIRUS-SPECIFIC T CELLS FOR THE TREATMENT OF REFRACTORY VIRAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Yalcin, Koray, et al.
Publicado: (2023)

A Case of Umbilical Artery Thrombosis in the Third Trimester of Pregnancy
por: Lutfallah, Fouad, et al.
Publicado: (2018)

Umbilical granuloma frequency of newborns in Third-line Hospital in Turkey
por: Tülin, Öztaş, et al.
Publicado: (2022)

Nanofiber Expansion of Umbilical Cord Blood Hematopoietic Stem Cells
por: Eskandari, F, et al.
Publicado: (2015)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE
por: Lehne, M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8n2blibtqrtiedibvcargkho5k